CA
NZ
UK
AU
IND
US
…
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, induced pluripotent stem cell (iPSC)-derived T‑ and NK‑cell therapies intended to treat hematologic and solid tumors. Long-term growth drivers include its iPSC platform that may enable scalable, off-the-shelf products, potential clinical data readouts, and manufacturing scale that could reduce costs compared with autologous approaches. Investors may find exposure to next-generation cell therapy technology attractive as it appears positioned to address supply and cost limitations of personalized treatments.
Material risks include early-stage clinical and regulatory uncertainty, high cash burn and financing needs, complex manufacturing and supply challenges, and intense competition from established cell therapy and gene-editing companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 |
| Income before tax | -130.84M | -95.78M | -53.58M | -244.77M | - |
| Net income | -130.93M | -95.82M | -54.66M | -245.98M | - |
| Selling general administrative | 31.86M | 19.23M | 9.49M | 5.77M | 81.39M |
| Gross profit | 5.20M | - | - | - | 2.48M |
| Reconciled depreciation | 8.44M | 3.75M | 1.40M | 0.25M | - |
| Ebit | -133.83M | -94.88M | -53.90M | -245.98M | - |
| Ebitda | -121.30M | -94.51M | -47.07M | -18.57M | - |
| Depreciation and amortization | 12.54M | 0.38M | 6.83M | 227.41M | - |
| Non operating income net other | 2.99M | -0.90M | - | - | - |
| Operating income | -133.83M | -94.88M | -53.90M | -245.98M | - |
| Other operating expenses | 139.03M | 94.88M | 49.18M | 20.03M | - |
| Interest expense | 1.10M | 1.27M | 0.38M | 0.00M | 0.00M |
| Tax provision | 0.09M | 0.04M | - | - | - |
| Net interest income | -1.40M | -1.27M | -0.38M | 0.00M | - |
| Non recurring | 10.00M | - | - | - | - |
| Income tax expense | 0.09M | 0.04M | 1.08M | 1.21M | - |
| Total revenue | 5.20M | 0.00M | 0.00M | 0.00M | 470.32M |
| Total operating expenses | 139.03M | 94.88M | 49.18M | 20.03M | - |
| Cost of revenue | - | - | - | - | 467.84M |
| Total other income expense net | 2.99M | -0.90M | 0.32M | 1.21M | - |
| Net income from continuing ops | -130.93M | -95.82M | -53.58M | -244.77M | - |
| Net income applicable to common shares | -130.93M | -95.82M | -53.58M | -244.77M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 360.69M | 486.54M | 437.38M | 106.78M | 90.90M |
| Intangible assets | - | - | - | 9.39M | - |
| Other current assets | 3.59M | 3.44M | 5.28M | 0.26M | 0.12M |
| Total liab | 175.94M | 183.81M | 41.14M | 213.19M | 182.75M |
| Total stockholder equity | 184.75M | 302.74M | 396.24M | -106.41M | -91.86M |
| Other current liab | 9.22M | 10.23M | 1.08M | 0.05M | 1.45M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -655.77M | -519.10M | -388.17M | -292.34M | -238.77M |
| Other liab | - | 111.55M | 2.02M | - | - |
| Other assets | 0.00M | 3.24M | 3.49M | 2.15M | 0.21M |
| Cash | 47.32M | 84.27M | 56.45M | 27.21M | 44.06M |
| Total current liabilities | 17.85M | 29.82M | 15.65M | 12.11M | 2.99M |
| Current deferred revenue | 4.37M | 7.15M | 5.32M | 3.74M | - |
| Net debt | 0.85M | -34.85M | -32.98M | -5.66M | -44.06M |
| Short term debt | 1.51M | 6.98M | 1.65M | 0.24M | - |
| Short long term debt | - | 6.50M | 1.04M | - | - |
| Short long term debt total | 48.17M | 49.41M | 23.46M | 21.55M | - |
| Other stockholder equity | 840.41M | 824.29M | 785.05M | 185.93M | 146.91M |
| Property plant equipment | - | 82.78M | 57.97M | 24.78M | 2.49M |
| Total current assets | 176.99M | 319.72M | 228.15M | 78.80M | 84.12M |
| Long term investments | 89.10M | 51.85M | 135.91M | 1.05M | 4.08M |
| Net tangible assets | - | 302.74M | 396.24M | -106.41M | -91.86M |
| Short term investments | 125.41M | 231.23M | 166.43M | 48.54M | 37.48M |
| Net receivables | 0.67M | 0.78M | 0.25M | 0.91M | 0.12M |
| Long term debt | - | 3.74M | 8.90M | 9.68M | - |
| Inventory | - | - | -0.25M | 1.88M | 2.34M |
| Accounts payable | 2.74M | 5.45M | 7.60M | 8.08M | 1.55M |
| Accumulated other comprehensive income | 0.11M | -2.46M | -0.65M | -0.00M | -0.00M |
| Common stock total equity | - | 0.01M | 0.01M | 0.00M | 0.00M |
| Retained earnings total equity | - | -519.10M | -388.17M | - | - |
| Non currrent assets other | 0.54M | 3.24M | 3.49M | 1.24M | 0.21M |
| Non current assets total | 183.70M | 166.82M | 209.22M | 27.98M | 6.77M |
| Capital lease obligations | 48.17M | 39.17M | 14.56M | 11.92M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 |
| Investments | 17.48M | -253.37M | -8.21M | -41.54M | - |
| Change to liabilities | 117.16M | -0.36M | 2.06M | 1.23M | - |
| Total cashflows from investing activities | -13.13M | -298.34M | -22.76M | -19.83M | - |
| Net borrowings | - | - | 9.73M | 9.73M | - |
| Total cash from financing activities | 27.16M | 417.77M | 47.69M | 74.84M | 98.09M |
| Change to operating activities | 10.74M | -0.95M | 2.80M | 1.03M | - |
| Net income | -130.93M | -95.82M | -53.58M | -244.77M | - |
| Change in cash | 28.08M | 30.43M | -16.34M | 38.84M | - |
| Begin period cash flow | 58.16M | 27.73M | 44.06M | 31.42M | - |
| End period cash flow | 86.24M | 58.16M | 27.73M | 70.26M | 31.42M |
| Total cash from operating activities | 14.05M | -89.00M | -41.27M | -16.17M | - |
| Issuance of capital stock | 27.16M | 381.24M | 0.00M | 74.84M | - |
| Depreciation | 8.44M | 3.75M | 1.40M | 0.25M | - |
| Change to inventory | - | - | - | - | 78.33M |
| Sale purchase of stock | 27.16M | 223.92M | - | - | - |
| Other cashflows from financing activities | -13.13M | 196.16M | 47.69M | -19.83M | - |
| Change to netincome | 10.67M | 4.66M | 5.95M | 226.09M | - |
| Capital expenditures | 30.60M | 44.97M | 9.82M | 2.46M | 11.12M |
| Cash flows other operating | 8.42M | -1.54M | - | - | - |
| Cash and cash equivalents changes | 28.08M | 30.43M | - | - | - |
| Change in working capital | 123.94M | -2.80M | 4.86M | 2.26M | - |
| Stock based compensation | 10.67M | 4.66M | 0.88M | 0.15M | - |
| Other non cash items | 1.93M | 1.21M | 0.44M | 225.95M | - |
| Free cash flow | -16.55M | -133.97M | -51.09M | -18.63M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics Inc |
- -% |
1.68 | - | - | 113.40 | 1.37 | 57.66 | -1.06 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
25 North 38th Street, Philadelphia, PA, United States, 19104
267 817 5790
152
| Name | Title | Year Born |
|---|---|---|
| Dr. Osvaldo Flores Ph.D. | Pres, CEO & Director | 1963 |
| Dr. Adrienne Farid Ph.D. | Chief Operations Officer | 1962 |
| Dr. Luis Borges | Chief Scientific Officer | 1962 |
| Mr. Douglas Carr CPA | VP of Fin. and Operations & Sec. | NA |
| Dr. Gregory Russotti Ph.D. | Chief Technology Officer | 1967 |
| Mr. Kenneth J. Dow J.D. | Head of Legal & Compliance | NA |
| Dr. Shane Williams Ph.D. | Chief People Officer | NA |
| Dr. Michael C. Diem | Chief Bus. Officer | 1971 |
| Dr. Hyam I. Levitsky M.D. | Pres of R&D | 1958 |
| Mr. Mark Wallet | Head of Immunology & VP | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...